Chokri Ben Lamine: Causes and Diagnostic Approach to PTT Prolongation
Chokri Ben Lamine, Adult Hematology and Stem Cell Transplantation Assistant Consultant at Oncology Center of Excellence at King Faisal Specialist Hospital and Research Center, shared a post on, recently shared on X:
“PTT Prolongation — Causes and Approach for Hema Fellows
Causes
- Factor deficiencies: VIII, IX, XI, XII
- Combined defects: Hemophilia A/B, vWD (type 2N), combined factor deficiencies
- Anticoagulants: UFH, argatroban, dabigatran
- Inhibitors: Lupus anticoagulant, acquired FVIII inhibitor
- Consumptive: DIC, massive transfusion
- Contact pathway defects: prekallikrein, HMW kininogen deficiency (no bleeding)
- Liver disease: decreased synthesis of multiple factors
Approach
- Check clinical context — bleeding vs thrombosis
- Repeat PTT — exclude lab error
- Mixing study:
- Corrects → factor deficiency → assay factors VIII, IX, XI, XII
- No correction → inhibitor → lupus anticoagulant or factor inhibitor workup
- If on anticoagulant — check drug level / anti-Xa / TT
- If prolonged with normal PT — think intrinsic pathway
- If prolonged PT and PTT — consider liver disease, DIC, multiple deficiencies
Written Exam Pearl
Isolated prolonged PTT + no bleeding → think lupus anticoagulant or contact factor deficiency.
OSCE Practical Tip
•Scenario: Post-op patient with thrombosis, PTT 65s, normal PT
Don’t rush to transfuse FFP — think lupus anticoagulant → do mixing study + DRVVT.
•Always ask about heparin flushes from lines before labs.
References:
1.Kitchens CS et al. Consultative Hemostasis and Thrombosis, 5th ed, 2023.
2.ISTH Guidelines 2024 — Lupus Anticoagulant Testing.
3.ASH Education Program 2022 — Approach to Abnormal Coagulation Tests.”
Stay updated on the latest with Hemostasis Today.
-
Sep 29, 2025, 12:54Microfluidic Technology Uncovers Ongoing TTP Disease Activity
-
Sep 29, 2025, 12:43Advancing Thrombosis Research: MRI-Based Methodology for Studying Thrombus Resolution
-
Sep 29, 2025, 05:58Samwel Mikaye on Understanding, Diagnosing, and Managing Deep Venous Thrombosis (DVT)
-
Sep 28, 2025, 14:08Mary Cushman: Dr Warkentin Is a Giant in Hematology
-
Sep 28, 2025, 13:31Michael Makris Highlights Vaccine Misinformation and Its Risks
-
Sep 29, 2025, 12:33Allison Wheeler: Some Days I Love Science a Little Bit More
-
Sep 29, 2025, 06:23Yudi Hardianto and Colleagues Give a Review on Stroke Rehabilitation in LMICs
-
Sep 29, 2025, 04:42Wolfgang Miesbach on the Bi8 Study: A Novel FVIII-Mimetic Antibody Gene Therapy for Haemophilia A
-
Sep 29, 2025, 04:16Salvador Payán Pernía on Equity Challenges in Access to Gene Therapy for Hemoglobinopathies
-
Sep 29, 2025, 04:02Nicolas Gendron: A Very Nice Demonstration by The Authors - Coffee is Associated with Reduced Risk of VTE
-
Sep 29, 2025, 05:06Sue Bacon on the Importance of Addressing Hospital-Acquired DVT and PE
-
Sep 24, 2025, 11:06Wolfgang Miesbach Reports Promising Results for New Subcutaneous von Willebrand Disease Therapy VGA039
-
Sep 23, 2025, 06:40Richard Buka: CSL Behring Have Announced a Collaboration with Dutch Biotech, VarmX
-
Sep 22, 2025, 07:10Aspirin Beyond the Heart․ Targeting PI3K-Altered Colorectal Cancer
-
Sep 22, 2025, 06:04ClearPlasma: A New Filter Technology to Enhance Clot Stability in Donated Plasma
-
Sep 29, 2025, 07:02Kambua Manundu: We Walked to Protest the Countless Lives of Women We Have Lost to Post Partum Hemorrhage
-
Sep 29, 2025, 06:41Ouma Oluga Unveiled Plans to Make Sickle Cell Screening Mandatory in Kenya at 80th UN General Assembly
-
Sep 29, 2025, 04:51Nathan Connell on Breakthrough Gene Therapy Advancing Care for People with Hemophilia
-
Sep 29, 2025, 04:28Emmeran Hauser: Fantastic to See First Results of Our Work in Europe
-
Sep 28, 2025, 10:33Côme Bommier: Burnout Is Common Among Hematology Professionals